The renaissance of neuroprotection in times of recanalization therapies

The recent publication of the ESCAPE-NA1 trial results (Hill et al., 2020) renewed the general interest surrounding the use of new and already established neuroprotective agents like Cerebrolysin^® in the acute treatment of stroke.

This interest is enhanced also by the evolution of diagnostic modalities, particularly neuroimaging, by ongoing changes in clinical trial methodologies, and by the establishment of highly effective recanalization strategies that help only certain subpopulations of stroke patients.

Re-evaluating neuroprotective treatment concepts that often failed to meet unrealistically high expectations in past trials is an important task in order to identify the best candidates for evidence-based neuroprotection after ischemic stroke

The results of ESCAPE-NA 1 but especially existing and new data from Cerebrolysin^® trials prove that the clinical development of Cerebrolysin^® is the most advanced of all available treatments in neuroprotection, particularly in combination with recanalization therapies.

Watch the video on our webinar website and get more information about this topic!